**Background**
Inflammation is a complex biological response to harmful stimuli, but chronic or excessive inflammation can lead to severe tissue damage and systemic diseases. Corticosteroids are widely utilized in clinical settings to modulate the immune response and reduce inflammation across various pathologies, including respiratory diseases, neurological injuries, and viral infections. For instance, in severe or critical COVID-19, glucocorticoids have been shown to improve patient outcomes by activating ACE2 and reducing levels of the pro-inflammatory cytokine IL-6. Given its potent immunomodulating properties, understanding the Methylprednisolone biological activity is essential for developing therapeutic strategies for inflammatory conditions. In this context, we will introduce a synthetic corticosteroid – Methylprednisolone.
**Definition**
Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. It is characterized by the Methylprednisolone Formula C22H30O5 and a molecular weight of 374.47.
**In Vitro and In Vivo Studies**
Methylprednisolone is extensively used in various experimental models to study inflammatory responses. Methylprednisolone in vitro studies demonstrate its utility in researching bronchial inflammation, acute bronchitis associated with arthritis, and various respiratory diseases. Furthermore, it has been shown to improve neurological recovery following acute spinal cord injury. In terms of cellular effects, Methylprednisolone acts as an activator of the pregnane X receptor (PXR). In human HepG2 (DPX-2) cells, 6-alpha-Methylprednisolone induced CYP3A4 expression after 24 hours with an EC50 of 12.6 μM, while it activated rat PXR in human HepG2 cells with an EC50 of 4 μM.
Methylprednisolone In Vivo research has provided critical insights into its pharmacokinetic profile and toxicity. In rat models, tissue distribution is nonlinear, with the highest concentration found in the liver (322.9 ng/ml) and the lowest in fat (2.74 ng/ml); however, its distribution in the central nervous system is limited due to P-glycoprotein-mediated blood-brain barrier efflux. Additionally, Methylprednisolone can be used to construct femoral head necrosis models. According to a specific Methylprednisolone protocol, administering 30 mg/kg via intramuscular injection on the second, third, and fourth days to 10-week-old male SD rats induces osteonecrosis. This process involves Methylprednisolone Autophagy, where the compound triggers osteoblast death through mitochondrial autophagy, ferroptosis, and apoptosis, resulting in significantly reduced bone volume fraction (BV/TV) and trabecular thickness (Tb.Th). In conclusion, Methylprednisolone is a potent synthetic corticosteroid effective for both anti-inflammatory research and the induction of steroid-induced osteonecrosis models.
Keywords
Methylprednisolone, 83-43-2, U 7532, U7532, U-7532, Glucocorticoid Receptor, Autophagy, SARS-CoV, Bacterial, SARS coronavirus, Inhibitor, inhibitor, inhibit
References
[1] Strupp, M., et al., Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med, 2004. 351(4): p. 354-61.
[2] Bracken, M.B., et al., A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med, 1990. 322(20): p. 1405-11.
[3] Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16(13):2382-2391.
[4] Fan Y,et al. Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. Bone Res. 2025 Jan 26;13(1):18.
[5] Yu R, et al. Physiologically Based Pharmacokinetic Modeling: The Reversible Metabolism and Tissue-Specific Partitioning of Methylprednisolone and Methylprednisone in Rats. Drug Metab Dispos. 2024 Jun 17;52(7):662-672.